Clinical Trial Update: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for WVE-210201 (Suvodirsen) in Duchenne muscular dystrophy shows termination after Phase 2/3 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• WVE-210201 (Suvodirsen) (suvodirsen)

Snippet

Sponsor: Wave Life Sciences Ltd. | Conditions: Duchenne Muscular Dystrophy | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-05-20